Repurposing as a strategy in the fight against COVID-19

Compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease.The EU-OPENSCREEN high capacity screening partner site, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Hamburg, Germany, applied high-content screening to a large drug repurposing collection investigating compounds ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2.

SARS-CoV-2 main protease (3CL-Pro), also termed M-Pro, is an attractive drug target as it plays a central role in viral replication by processing the viral polyproteins pp1a and pp1ab at multiple distinct cleavage sites. The results of the repurposing screen can be found here.